Peripheral Nerve Damage, Spinal Cord Injury, Stroke, TBI
Conditions
Brief summary
This study will evaluate the safety and performance of the Spatial StimeMD (SSMD) medical device in people with multiple sclerosis (MS). The SSMD device is intended to support patients through a non-invasive stimulation program. The study will assess changes in MS-related symptoms and physical function using clinical assessments and patient-reported outcomes.
Detailed description
This is a clinical investigation of the Spatial StimeMD (SSMD) medical device in participants diagnosed with multiple sclerosis (MS). The purpose of the study is to evaluate the safety and performance of the device in a controlled clinical setting. Participants will be followed according to the study schedule and will undergo assessments of MS symptoms, physical function, and other relevant clinical outcomes. Safety will be assessed through monitoring of adverse events and other safety parameters throughout the study. Study data will be collected and reviewed according to the protocol, including verification against source documentation as required.
Interventions
DEVICESSMD
SSMD device-based therapy delivered in addition to conventional therapy. Participants receive 18 sessions, 30 minutes each, administered 6 sessions per week over 3 weeks.
Functional electrical stimulation (FES) delivered in addition to conventional therapy. Participants receive 18 sessions, 30 minutes each, administered 6 sessions per week over 3 weeks.
Sponsors
Motion Informatics LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
This is an open-label study. No masking/blinding is implemented due to the nature of the device interventions and treatment delivery
Intervention model description
Participants will be randomized (1:1) into two parallel groups to receive either SSMD plus conventional therapy or FES plus conventional therapy
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Adult men and women aged 18-80 years. 2. Clinically confirmed diagnosis of stroke, TBI, spinal cord injury, or peripheral nerve injury within the past 24 months. 3. Presence of moderate to severe neuromotor impairment in at least one limb, as evidenced by medical evaluation and a score \<35 on the Fugl-Meyer Upper Extremity motor subscale (FMA-UE). 4. Capacity and willingness to provide informed consent, indicating understanding of the study purpose, procedures, and potential risks and benefits. 5. Subject is able to adhere to the study schedule and cognitively capable to perform the treatment. 6. Stable medical condition without ongoing acute complications that could interfere with participation.
Exclusion criteria
1. Presence of contraindications to electrical stimulation (ES), including implanted electronic medical devices (e.g., Cardiac demand pacemakers, Implantable pacemakers, Implantable cardioverter defibrillators, Implantable neurostimulators, Body-worn devices such as insulin pumps) or conditions that may be exacerbated by electrical stimulation (e.g., uncontrolled epilepsy). 2. Individuals with medical conditions, which are prone to seizures or motion sensitivity, at the investigator's discretion. 3. Individuals with light sensitivity, as the AR component may involve visual stimuli that could cause discomfort or adverse reactions in these patients. 4. Individuals with acute physical conditions or injuries that could interfere with the proper placement of the electrodes or safe use of the device. 5. Presence of spinal shock or unresolved acute spinal cord dysfunction, characterized by complete loss of reflexes, flaccid paralysis, or autonomic instability. 6. Current participation in other clinical trials that could confound the study results. 7. Severe cognitive impairment that precludes the ability to provide informed consent or reliably adhere to the study protocol, as determined by cognitive screening and clinical judgment. 8. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Fugl-Meyer Upper Extremity (FMA-UE) motor score | Baseline to post-treatment (end of treatment, 3 weeks) | Change from baseline in Fugl-Meyer Assessment Upper Extremity (Motor Function Subscale) The Fugl-Meyer Assessment Upper Extremity motor score is a clinician-rated measure of upper limb motor impairment following neurological injury. Scores range from 0 to 66, with higher scores representing less impairment and better motor function. Time Frame: Baseline to post-treatment (3 weeks). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in Movement range and movement quality (SSMD assessment mode) | Baseline to post-treatment (end of treatment, Week 3) | Change from baseline to post-treatment in movement range and movement quality as assessed using the SSMD system assessment mode. |
| Change in Functional Independence Measure (FIM) score | Baseline to post-treatment (end of treatment, Week 3) | Change from baseline to post-treatment in activities of daily living as measured by the Functional Independence Measure (FIM) total score (range 18-126, higher scores indicate greater independence and better functional outcome). Time Frame: Baseline to end of treatment (Week 3). |
| Change in EMG signal strength (threshold) | Baseline to post-treatment (end of treatment, Week 3) | Change from baseline to post-treatment in electromyography (EMG) signal strength (threshold) during device-assisted assessment. |
Countries
Poland
Outcome results
None listed